LI-RADS各分类中肝细胞癌百分比:CT与MRI的系统综述与Meta分析
结果显示三种模态在各分类间肝细胞癌百分比无显著差异,LR-5均约95%-96%,LR-M和LR-5V/LR-TIV多数为恶性。
要点
- LR-5的肝细胞癌百分比在CT、ECA-MRI和Gx-MRI均约95%-96%,模态间无差异。
- LR-M和LR-5V/LR-TIV观察灶多数为恶性(93%-100%和99%-100%),无论何种模态。
- LR-1未报告肝细胞癌或非肝细胞癌恶性肿瘤,LR-2的肝细胞癌百分比较低(1%-10%)。
诊断标准与关键数值
- LR-1:任何模态均未报告肝细胞癌或非肝细胞癌恶性肿瘤。
- LR-2:CT、ECA-MRI、Gx-MRI的肝细胞癌合并百分比分别为10%、6%、1%(P = .16)。
- LR-3:CT、ECA-MRI、Gx-MRI的肝细胞癌合并百分比分别为48%、31%、38%(P = .42)。
- LR-4:CT、ECA-MRI、Gx-MRI的肝细胞癌合并百分比分别为76%、64%、77%(P = .62)。
- LR-5:CT、ECA-MRI、Gx-MRI的肝细胞癌合并百分比分别为96%、95%、96%(P = .76)。
临床应用与阅片要点
- 日常阅片可依据LI-RADS分类报告肝细胞癌概率,LR-5高度提示肝细胞癌,LR-M和LR-5V/LR-TIV需警惕恶性。
- CT与两种MRI对比剂方案在各分类的肝细胞癌百分比无差异,模态选择不影响LI-RADS分类的恶性概率解读。
局限性
- 纳入研究间异质性可能影响合并结果,原文未具体说明异质性来源。
- 仅纳入使用2014、2017或2018版LI-RADS的研究,未涵盖更早版本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The Liver Imaging Reporting and Data System (LI-RADS) CT and MRI algorithm applies equally to CT, MRI with extracellular contrast agents (ECA-MRI), and MRI with gadoxetate (Gx-MRI). Purpose To estimate pooled percentages of hepatocellular carcinoma (HCC) and overall malignancy for each LI-RADS category with CT and MRI. Materials and Methods MEDLINE and EMBASE databases were searched for research articles (January 2014-April 2021) reporting the percentages of observations in each LI-RADS category with use of versions 2014, 2017, or 2018. Study design, population characteristics, imaging modality, reference standard, and numbers of HCC and non-HCC malignancies in each category were recorded. A random-effects model evaluated the pooled percentage of HCC and overall malignancy for each category. Results There were 49 studies with 9620 patients and a total 11 562 observations, comprising 7921 HCCs, 1132 non-HCC malignancies, and 2509 benign entities. No HCC or non-HCC malignancies were reported with any modality in the LR-1 category. The pooled percentages of HCC for CT, ECA-MRI, and Gx-MRI, respectively, were 10%, 6%, and 1% for LR-2 (P = .16); 48%, 31%, and 38% for LR-3 (P = .42); 76%, 64%, and 77% for LR-4 (P = .62); 96%, 95%, and 96% for LR-5 (P = .76); 88%, 76%, and 78% for LR-5V or LR-TIV (tumor in vein) (P = .42); and 20%, 30%, and 35% for LR-M (P = .32). Most LR-M (93%-100%) and LR-5V or LR-TIV (99%-100%) observations were malignant, regardless of modality. Conclusion There was no difference in percentages of hepatocellular carcinoma and overall malignancy between CT, MRI with extracellular contrast agents, and MRI with gadoxetate for any Liver Imaging Reporting and Data System categories. © RSNA, 2023 Supplemental material is available for this article See also the editorial by Ronot in this issue.
引用
- Lee, Kim, Shin, et al. Percentages of Hepatocellular Carcinoma in LI-RADS Categories with CT and MRI: A Systematic Review and Meta-Analysis. Radiology. 2023. PMID: 36625748. doi:10.1148/radiol.220646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。